APVO
Aptevo Therapeutics Inc
$
1.470
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.530
Open
1.530
VWAP
1.49
Vol
773.74K
Mkt Cap
4.83M
Low
1.450
Amount
1.15M
EV/EBITDA(TTM)
--
Total Shares
4.08M
EV
-4.97M
EV/OCF(TTM)
--
P/S(TTM)
--
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
0.000
-100%
--
--
-1.900
-98.94%
--
--
-2.090
-99.41%
Estimates Revision
The market is revising No Change the revenue expectations for Aptevo Therapeutics Inc. (APVO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -43.24%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-43.24%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Aptevo Therapeutics Inc (APVO.O) is -0.14, compared to its 5-year average forward P/E of -1.00. For a more detailed relative valuation and DCF analysis to assess Aptevo Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.00
Current PE
-0.14
Overvalued PE
1.49
Undervalued PE
-3.49
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.54
Current PS
1.47
Overvalued PS
10.43
Undervalued PS
-3.35
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+3.35%
-6.23M
Operating Profit
FY2025Q2
YoY :
+5.46%
-6.20M
Net Income after Tax
FY2025Q2
YoY :
-99.32%
-8.40
EPS - Diluted
FY2025Q2
N/A
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
21.1K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
APVO News & Events
Events Timeline
2025-09-16 (ET)
2025-09-16
08:51:15
Aptevo Reports 100% Remission Rate for Mipletamig in RAINIER Cohort 3
2025-09-04 (ET)
2025-09-04
08:47:50
Aptevo Therapeutics Enhances Cancer Treatment Portfolio with APVO452 and APVO451
2025-08-13 (ET)
2025-08-13
08:51:29
Aptevo Therapeutics highlights APVO442 preclinical candidate for prostate cancer
Sign Up For More Events
Sign Up For More Events
News
9.5
09-18BenzingaGold Declines by More Than 1%; Darden Reports Disappointing Earnings
9.5
09-18TipRanksThursday's Major Stock Market Highlights: Morning News Summary!
4.5
09-18BenzingaNasdaq Rises by 100 Points as US Initial Jobless Claims Decrease
Sign Up For More News
People Also Watch
FAQ
What is Aptevo Therapeutics Inc (APVO) stock price today?
The current price of APVO is 1.47 USD — it has decreased -5.16 % in the last trading day.
What is Aptevo Therapeutics Inc (APVO)'s business?
What is the price predicton of APVO Stock?
What is Aptevo Therapeutics Inc (APVO)'s revenue for the last quarter?
What is Aptevo Therapeutics Inc (APVO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Aptevo Therapeutics Inc (APVO)'s fundamentals?
How many employees does Aptevo Therapeutics Inc (APVO). have?